Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Realcan Pharmaceutical Group Co., Ltd. (002589.SZ)
CNY2.83
+0.09 (+3.28%)
CN SHZ Healthcare Medical - Distribution
Address
No. 326, Airport Road 264004
Yantai, CN
Yantai, CN
CEO
Xu Han
Website
realcan.cn
IPO
2011-06-10
ISIN CNE1000013X5
Description
Realcan Pharmaceutical Group Co., Ltd. operates as a global supplier, distributing pharmaceuticals, vaccines, medical devices, and consumable medical products to healthcare institutions across the world. Beyond its core distribution activities, the company offers a suite of specialized services, including comprehensive medical logistics, third-party logistics solutions, disinfection and sterilization, and equipment leasing, alongside full-service hospital logistics support. Its operational reach spans diverse areas such as drug distribution, academic support services, medical diagnostics, financial technology applications, traditional Chinese medicine, digital health solutions, professional logistics, and integrated equipment management. The company, initially incorporated as Realcan Pharmaceutical Co., Ltd., adopted its current designation in December 2018. Realcan was established in 2004 and is headquartered in Yantai, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY2.83
+0.09 (+3.28%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
61M
Beta
0.27
Float Shares
783.96M
Free Float %
68.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.35% | -2.05% | -11.69% | -13.55% | -8.01% | -10.87% | -3.04% | -20.50% | -42.02% | -75.62% | -97.78% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2.83
DCF (Unlevered)
5.12
+80.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
89% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 5 | 0 |
| Buy | 3 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
0.77
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Distribution: +5.6%-8.4% Q1'26: -2.8% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%-27.0% Q1'26: -26.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%-2.1% Q1'26: -0.5% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+2.5% Q1'26: +4.2% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+2.2% Q1'26: +5.1% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%+6.8% Q1'26: -0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×17.98× Q1'26: 17.49× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
Dec 2031 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
9.75B
est: 9.67B (+0.8%)
|
15.62B
est: 15.09B (+3.5%)
|
23.29B
est: 15.09B (+54.3%)
|
33.92B
est: 23.45B (+44.6%)
|
35.26B
est: 33.92B (+3.9%)
|
27.23B
est: 37.92B (-28.2%)
|
38.71B
est.
|
21.06B
est: 43.90B (-52.0%)
|
8.03B
est: 50.88B (-84.2%)
|
12.31B
est: 50.88B (-75.8%)
|
7.30B
est: 23.45B (-68.9%)
|
33.92B
33.92B – 33.92B
+44.7% YoY
|
37.92B
37.92B – 37.92B
+11.8% YoY
|
38.71B
38.71B – 38.71B
+2.1% YoY
|
43.90B
43.90B – 43.90B
+13.4% YoY
|
50.88B
50.88B – 50.88B
+15.9% YoY
|
50.88B
50.88B – 50.88B
+0.0% YoY
|
| EBITDA |
450.69M
est: 312.11M (+44.4%)
|
1.06B
est: 486.94M (+118.1%)
|
2.23B
est: 486.94M (+357.0%)
|
2.95B
est: 756.55M (+289.8%)
|
1.29B
est: 1.09B (+17.9%)
|
1.92B
est: 1.22B (+56.7%)
|
1.25B
est.
|
1.36B
est: 1.42B (-3.7%)
|
403.11M
est: 1.64B (-75.4%)
|
-1.02B
est: 1.64B (-162.3%)
|
360.68M
est: 2.26B (-84.0%)
|
3.27B
3.27B – 3.27B
+44.7% YoY
|
3.65B
3.65B – 3.65B
+11.8% YoY
|
3.73B
3.73B – 3.73B
+2.1% YoY
|
4.23B
4.23B – 4.23B
+13.4% YoY
|
4.90B
4.90B – 4.90B
+15.9% YoY
|
4.90B
4.90B – 4.90B
+0.0% YoY
|
| EBIT |
407.57M
est: 96.63M (+321.8%)
|
983.27M
est: 150.75M (+552.2%)
|
2.08B
est: 150.75M (+1,278.7%)
|
2.71B
est: 234.22M (+1,058.9%)
|
1.02B
est: 338.83M (+199.7%)
|
1.63B
est: 378.78M (+329.2%)
|
386.70M
est.
|
1.06B
est: 438.51M (+142.8%)
|
187.93M
est: 508.24M (-63.0%)
|
-1.30B
est: 508.24M (-355.3%)
|
181.54M
est: 1.47B (-87.7%)
|
2.13B
2.13B – 2.13B
+44.7% YoY
|
2.39B
2.39B – 2.39B
+11.8% YoY
|
2.44B
2.44B – 2.44B
+2.1% YoY
|
2.76B
2.76B – 2.76B
+13.4% YoY
|
3.20B
3.20B – 3.20B
+15.9% YoY
|
3.20B
3.20B – 3.20B
+0.0% YoY
|
| Net Income |
235.94M
est: 358.68M (-34.2%)
|
590.76M
est: 578.31M (+2.2%)
|
1.01B
est: 578.31M (+74.3%)
|
771.18M
est: 1.01B (-23.7%)
|
-927.80M
est: 1.06B (-187.9%)
|
261.30M
est: 918.19M (-71.5%)
|
587.04M
est.
|
131.18M
est: 662.30M (-80.2%)
|
20.32M
est: 737.56M (-97.2%)
|
-1.83B
est: 737.56M (-348.2%)
|
16.07M
est: 1.08B (-98.5%)
|
1.13B
1.13B – 1.13B
+4.4% YoY
|
980.34M
980.34M – 980.34M
-13.0% YoY
|
626.78M
626.78M – 626.78M
-36.1% YoY
|
707.13M
707.13M – 707.13M
+12.8% YoY
|
787.49M
787.49M – 787.49M
+11.4% YoY
|
787.49M
787.49M – 787.49M
+0.0% YoY
|
| SGA |
602.65M
est: 616.74M (-2.3%)
|
1.28B
est: 962.21M (+33.4%)
|
2.20B
est: 962.21M (+128.8%)
|
3.28B
est: 1.49B (+119.2%)
|
3.77B
est: 2.16B (+74.3%)
|
3.08B
est: 2.42B (+27.2%)
|
2.47B
est.
|
2.57B
est: 2.80B (-8.1%)
|
824.37M
est: 3.24B (-74.6%)
|
1.46B
est: 3.24B (-55.1%)
|
269.23M
est: 2.22B (-87.9%)
|
3.21B
3.21B – 3.21B
+44.7% YoY
|
3.59B
3.59B – 3.59B
+11.8% YoY
|
3.66B
3.66B – 3.66B
+2.1% YoY
|
4.15B
4.15B – 4.15B
+13.4% YoY
|
4.81B
4.81B – 4.81B
+15.9% YoY
|
4.81B
4.81B – 4.81B
+0.0% YoY
|
| EPS |
0.19
est: 0.24 (-20.3%)
|
0.44
est: 0.38 (+14.5%)
|
0.67
est: 0.38 (+74.4%)
|
0.51
est: 0.67 (-24.1%)
|
-0.62
est: 0.70 (-188.4%)
|
0.18
est: 0.61 (-70.5%)
|
0.39
est.
|
0.09
est: 0.44 (-79.5%)
|
0.01
est: 0.49 (-97.2%)
|
-1.24
est: 0.49 (-353.1%)
|
0.01
est: 0.67 (-98.5%)
|
0.70
0.70 – 0.70
+4.4% YoY
|
0.61
0.61 – 0.61
-13.0% YoY
|
0.39
0.39 – 0.39
-36.1% YoY
|
0.44
0.44 – 0.44
+12.8% YoY
|
0.49
0.49 – 0.49
+11.4% YoY
|
0.49
0.49 – 0.49
+0.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-25 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-70.35M
OE per share TTM
-0.05
Owner's Yield
-1.63%
Maintenance CapEx ratio
173.79%
Maint CapEx / Avg PPE
14.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 42.7K | 0.29% |
| 2 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 5.2K | 0.48% |
| 3 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 11.8K | 0.26% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 583.6K | 0.06% |
| 5 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 937.75 | 0.22% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.8K | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.5K | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 669.10 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 77.31 | 0.22% |
| 10 | Vanguard Retirement Income ETF Portfolio VRIF.TO | 0.00% | 25.39 | 0.31% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
56.0K
Shares Outstanding
1.14B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bo Yang | Vice President & Director | — | male |
| Chunlin Han | Vice President & Director | — | male |
| Mingtao Yan | Vice President | — | male |
| Qing Yan Cao | Accounting Supervisor | — | — |
| Xu Han | President & Chairman | — | male |
| Yi Feng | Chief Financial Officer & Vice President | — | female |
| Zhe Li | Vice President, Secretary & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002589.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
